Welcome to BioMarket Group!

Publication Series

In this section you will find Publication Series market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.

Items 1 to 15 of 68 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Ascending Direction
  1. Pancreatic Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 385 companies plus partners who are today developing 444 drugs targeting pancreatic cancer in development. across 352 different targets. In addition, there is 1 suspended drug and another 136 drugs where development has been ceased. Learn More

  2. IL-7 Signaling Pathway in Oncology Drug Pipeline Update

    $750.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 90 companies plus partners who are today developing 95 IL-7 pathway targeting drugs in 389 developmental projects in cancer across 85 different targets. In addition, there is 1 suspended drug and another 36 drugs where development has been ceased. Learn More

  3. Colorectal Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 426 companies plus partners who are today developing 509 drugs targeting colorectal cancer in development. across 346 different targets. In addition, there are 6 suspended drugs and another 211 drugs where development has been ceased. Learn More

  4. TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 396 companies plus partners who are today developing 509 TGF-beta receptor pathway targeting drugs in 1845 developmental projects in cancer across 259 different targets. In addition, there are 2 suspended drugs and another 265 drugs where development has been ceased. Learn More

  5. Renal Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 243 companies plus partners who are today developing 270 drugs targeting renal cancer in development. across 233 different targets. In addition, there are 3 suspended drugs and another 95 drugs where development has been ceased. Learn More

  6. IL-5 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 163 companies plus partners who are today developing 209 IL-5 pathway targeting drugs in 891 developmental projects in cancer across 146 different targets. In addition, there are 2 suspended drugs and another 86 drugs where development has been ceased. Learn More

  7. Biologicals in Oncology Drug Pipeline Update

    $3,675.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 1371 companies plus partners who are today developing 2823 biological drugs in 6088 developmental projects in cancer across 801 different targets. In addition, there are 25 suspended drugs and another 1050 drugs where development has been ceased. Learn More

  8. Melanoma Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 374 companies plus partners who are today developing 403 drugs targeting melanoma in development. across 317 different targets. In addition, there are 2 suspended drugs and another 155 drugs where development has been ceased. Learn More

  9. IL-3 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 257 companies plus partners who are today developing 339 IL-3 pathway targeting drugs in 1225 developmental projects in cancer across 164 different targets. In addition, there are 4 suspended drugs and another 131 drugs where development has been ceased. Learn More

  10. Nucleic Acid Therapies in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 308 companies plus partners who are today developing 381 nucleic acid therapy drugs in 775 developmental projects in cancer across 251 different targets. In addition, there are 9 suspended drugs and another 211 drugs where development has been ceased. Learn More

  11. Apoptosis in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 460 companies plus partners who are today developing 588 apoptotic drugs in 2586 developmental projects in cancer across 389 different targets. In addition, there are 13 suspended drugs and another 307 drugs where development has been ceased. Learn More

  12. IL-1 Signaling Pathway in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 111 companies plus partners who are today developing 113 IL-1 pathway targeting drugs in 415 developmental projects in cancer across 96 different targets. In addition, there are 2 suspended drugs and another 55 drugs where development has been ceased. Learn More

  13. Leukemia Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 456 companies plus partners who are today developing 631 leukemia drugs in 913 developmental projects in cancer across 333 different targets. In addition, there are 8 suspended drugs and another 164 drugs where development has been ceased. Learn More

  14. B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 309 companies plus partners who are today developing 424 B cell receptor pathway targeting drugs in 1700 developmental projects in cancer across 198 different targets. In addition, there are 5 suspended drugs and another 154 drugs where development has been ceased. Learn More

  15. Gene Therapy in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 125 companies plus partners who are today developing 103 gene therapy drugs in 262 developmental projects in cancer across 107 different targets. In addition, there are 4 suspended drugs and another 105 drugs where development has been ceased. Learn More

Items 1 to 15 of 68 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Ascending Direction

Publication Series

In this section you will find Publication Series market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.

Items 1 to 15 of 68 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Ascending Direction
  1. Pancreatic Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 385 companies plus partners who are today developing 444 drugs targeting pancreatic cancer in development. across 352 different targets. In addition, there is 1 suspended drug and another 136 drugs where development has been ceased. Learn More

  2. IL-7 Signaling Pathway in Oncology Drug Pipeline Update

    $750.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 90 companies plus partners who are today developing 95 IL-7 pathway targeting drugs in 389 developmental projects in cancer across 85 different targets. In addition, there is 1 suspended drug and another 36 drugs where development has been ceased. Learn More

  3. Colorectal Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 426 companies plus partners who are today developing 509 drugs targeting colorectal cancer in development. across 346 different targets. In addition, there are 6 suspended drugs and another 211 drugs where development has been ceased. Learn More

  4. TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 396 companies plus partners who are today developing 509 TGF-beta receptor pathway targeting drugs in 1845 developmental projects in cancer across 259 different targets. In addition, there are 2 suspended drugs and another 265 drugs where development has been ceased. Learn More

  5. Renal Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 243 companies plus partners who are today developing 270 drugs targeting renal cancer in development. across 233 different targets. In addition, there are 3 suspended drugs and another 95 drugs where development has been ceased. Learn More

  6. IL-5 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 163 companies plus partners who are today developing 209 IL-5 pathway targeting drugs in 891 developmental projects in cancer across 146 different targets. In addition, there are 2 suspended drugs and another 86 drugs where development has been ceased. Learn More

  7. Biologicals in Oncology Drug Pipeline Update

    $3,675.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 1371 companies plus partners who are today developing 2823 biological drugs in 6088 developmental projects in cancer across 801 different targets. In addition, there are 25 suspended drugs and another 1050 drugs where development has been ceased. Learn More

  8. Melanoma Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 374 companies plus partners who are today developing 403 drugs targeting melanoma in development. across 317 different targets. In addition, there are 2 suspended drugs and another 155 drugs where development has been ceased. Learn More

  9. IL-3 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 257 companies plus partners who are today developing 339 IL-3 pathway targeting drugs in 1225 developmental projects in cancer across 164 different targets. In addition, there are 4 suspended drugs and another 131 drugs where development has been ceased. Learn More

  10. Nucleic Acid Therapies in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 308 companies plus partners who are today developing 381 nucleic acid therapy drugs in 775 developmental projects in cancer across 251 different targets. In addition, there are 9 suspended drugs and another 211 drugs where development has been ceased. Learn More

  11. Apoptosis in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 460 companies plus partners who are today developing 588 apoptotic drugs in 2586 developmental projects in cancer across 389 different targets. In addition, there are 13 suspended drugs and another 307 drugs where development has been ceased. Learn More

  12. IL-1 Signaling Pathway in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 111 companies plus partners who are today developing 113 IL-1 pathway targeting drugs in 415 developmental projects in cancer across 96 different targets. In addition, there are 2 suspended drugs and another 55 drugs where development has been ceased. Learn More

  13. Leukemia Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 456 companies plus partners who are today developing 631 leukemia drugs in 913 developmental projects in cancer across 333 different targets. In addition, there are 8 suspended drugs and another 164 drugs where development has been ceased. Learn More

  14. B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 309 companies plus partners who are today developing 424 B cell receptor pathway targeting drugs in 1700 developmental projects in cancer across 198 different targets. In addition, there are 5 suspended drugs and another 154 drugs where development has been ceased. Learn More

  15. Gene Therapy in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 125 companies plus partners who are today developing 103 gene therapy drugs in 262 developmental projects in cancer across 107 different targets. In addition, there are 4 suspended drugs and another 105 drugs where development has been ceased. Learn More

Items 1 to 15 of 68 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Ascending Direction